Health
Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain – News-Medical.Net
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the…
Last September, researchers at the University of Washington, USA, reported the development of computer-designed small proteins – ‘miniproteins’ – that can target the receptor-binding domain (RBD) on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic.
This work was published in the journal Science, claiming the lead antiviral miniprotein candidate, named LCB1, which exhibited better protective…
-
General16 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General18 hours agoBack-to-back rate cuts tipped when Reserve Bank meets
-
Noosa News18 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
Business21 hours agoThese ASX 200 shares could rise 55% to 65%